Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
grade F 42.96 -2.85% -1.26
QURE closed down 2.85 percent on Friday, October 18, 2019, on 65 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical QURE trend table...

Date Alert Name Type % Chg
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -2.85%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.85%
Pocket Pivot Bullish Swing Setup -2.85%
Narrow Range Bar Range Contraction -2.85%
NR7 Range Contraction -2.85%
Stochastic Reached Overbought Strength -2.85%
Weak + Overbought Other -2.85%
Weak, Overbought and Reversal Signs Reversal -2.85%

Older signals for QURE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biopharmaceutical Biology Diseases Gene Therapy Genetics Parkinson's Disease Applied Genetics Gene Delivery Treatment Of Hemophilia Adeno Associated Virus AAV Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B
Is QURE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 82.49
52 Week Low 21.98
Average Volume 564,720
200-Day Moving Average 54.7932
50-Day Moving Average 47.842
20-Day Moving Average 41.9255
10-Day Moving Average 42.791
Average True Range 2.2627
ADX 33.27
+DI 18.1246
-DI 27.7768
Chandelier Exit (Long, 3 ATRs ) 41.4619
Chandelier Exit (Short, 3 ATRs ) 42.9881
Upper Bollinger Band 46.1712
Lower Bollinger Band 37.6798
Percent B (%b) 0.62
BandWidth 20.253545
MACD Line -1.2651
MACD Signal Line -2.0406
MACD Histogram 0.7755
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 25.6 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -15.23
Price-to-Sales 16.30
Price-to-Book 14.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.74
Resistance 3 (R3) 45.79 44.91 45.27
Resistance 2 (R2) 44.91 44.20 44.88 45.12
Resistance 1 (R1) 43.93 43.76 43.50 43.89 44.97
Pivot Point 43.06 43.06 42.84 43.03 43.06
Support 1 (S1) 42.08 42.35 41.64 42.03 40.95
Support 2 (S2) 41.21 41.91 41.18 40.80
Support 3 (S3) 40.23 41.21 40.65
Support 4 (S4) 40.18